Avivagen Inc. (VIVXF)(VIV:CA) – Initiation Coverage of Avivagen: Well positioned Early Stage Ag-biotech Company

Monday, March 01, 2021

Avivagen Inc. (VIVXF)(VIV:CA)
Initiation Coverage of Avivagen: Well positioned Early Stage Ag-biotech Company

Avivagen Inc is a Canadian based company operating in the healthcare sector. It develops science-based, natural health products for animals. It develops and commercializes products for livestock feeds to replace antibiotics for growth promotion and to help prevent disease by supporting the animal’s own health defenses. Its product range includes OxC-beta, Vivamune health chews, Oximunol chewable tablets, and Carotenoid Oxidation products.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Initiating Coverage. We are initiating research coverage on Avivagen, Inc. Avivagen is an early-stage revenue company focused on developing and commercializing products for livestock, companion animals, and humans. We believe the Company is at an inflection point with significant sales increases just around the corner and presents a favorable risk/reward proposition.

    Novel Therapeutic.  Avivagen’s novel, proprietary technology, OxC-beta, helps support optimal immune function and helps animals achieve their full growth and productivity potential. The natural compound’s benefits have been illustrated in over 40 research studies and trials. Avivagen has broad patent protection on OxC-beta …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

QuickChek – March 1, 2021



One Stop Systems up 30% midday

One Stop Systems up 30% in midday trading

Research, News & Market Data on One Stop Systems

Watch recent presentation from NobleCon17



Noble Capital Markets Initiates Research Coverage on Avivagen, Inc.

Noble Capital Markets is initiating research coverage on Avivagen, Inc. Avivagen is an early-stage revenue company focused on developing and commercializing products for livestock, companion animals, and humans.

Research, News & Market Data on Avivagen

Watch Avivagen’s recent presentation from NobleCon 17



ACCO Brands Corporation Announces Private Offering

ACCO Brands Corporation announced a private offering of $650 million of senior unsecured notes due 2029.

Research, News & Market Data on ACCO Brands

Watch ACCO Brand’s recent presentation from NobleCon17



electroCore Inc. Announces Exclusive Distribution Agreement with Medistar

electroCore Inc. announced that it has entered into an agreement whereby Medistar will serve as the exclusive distributor of gammaCore Sapphire™ in Australia

Research, News & Market Data on electroCore

Watch recent presentation from NobleCon17



Endeavour Silver released its financial results for the fourth quarter and year

electroCore Inc. reports $19.9 Million Earnings in the Fourth Quarter, 2020 and $1.2 Million Earnings for the Full Year, 2020

Research, News & Market Data on electroCore

Watch recent presentation from NobleCon17

Stay up to date. Follow us:

What Will the Stock Market do in the Spring?

 


Looking Back then Forward, What May Be in Store for the U.S. Stock Markets

 

The stock market performance for March and April could hinge on a number of questions investors are considering right now. What they’d like to know is: Will a stimulus bill pass in the coming weeks (positive)? Will there be a continued reduction in deaths reported due to the pandemic (positive)? Will there be a continued move up in interest rates (negative)? Will inflation rise and begin to force the Fed to choose between subdued growth or higher prices (both negative)?

The stimulus bill and distribution of any approved spending have been delayed much longer than expected. Any further delays could cause market participants discomfort. Should the market continue to show signs that the forward momentum has diminished, or giving up ground, the fear-of-missing-out (FOMO) investors may leave stocks, possibly to higher interest rates.

 

 

Look Back

Looking back over the past six months, the Nasdaq 100 gained 10.13%, which is admirable in any year. The S&P 500 index fared just a bit better at 10.67%. The small-cap Russell 2000 index, which had been performing below the other indices, finally got recognition and increased by 40.55%.

Within the reignited small-cap stocks, small-cap value (IWN) has returned 14.09% in three months’ time, while small-cap growth trailed by a little with a 12.63% return. Overall, during the three-month period, small-caps (IWM) returned 13.25%.

 

 

Hottest Market Sectors

Over the same three months (December – February), the industry sectors (S&P) in many cases have reversed direction from six months ago. Energy, which had been beaten up at the first hint of a pandemic, rose 23.94%. Financials are benefitting from a steepening yield curve and a large supply of cash in the system. Financials are up 13.74% in just three months’ time. Communications companies turned in 9.93% for the period. Health care is up 4.27% and materials 3.61%. Utility stocks that are popular for their dividend payments are lower by 8.61%, as higher interest rates would provide alternatives for income investors.

 

 

Take-Away

The market is still waiting on a lot of information. A stimulus package could dramatically change the mood of investors, and checks in the hands of those already with discretionary income have in the past caused some of that money to wind up in the stock market. Signs of a complete economic reopening would certainly improve expectations going forward as we are now in the month when the first 14-day lockdown was instituted a year ago. It still remains to be seen what the President’s “Made in America” program will really look like as he is at the same time pushing to increase the cost of American-made goods. These conflicts of priority are normal in politics, all we can expect from ourselves as investors are to determine where the money will flow with each change and each step back toward normalcy, then be then early.

 

Suggested Reading

Why Elevated Employment Isn’t Hurting Stocks

What Stocks do You Buy When the Dollar Goes Down?

Managing Investment Portfolio Risk

 

 

Sources:

Koyfin.com

 

Stay up to date. Follow us:

           


Stay up to date. Follow us:

Release – Kuya Silver (KUYAF)(KUYA:CA) – Closes Acquisition of Properties in Northern Ontario and Launches the Silver Kings Project


Kuya Silver Closes Acquisition of Properties in Northern Ontario and Launches the Silver Kings Project

 

Vancouver, British Columbia–(Newsfile Corp. – March 1, 2021) – Kuya Silver Corporation (CSE: KUYA) (OTCQB: KUYAF) (FSE: 6MR1) (the “Company” or “Kuya“) is pleased to announce that pursuant to a share purchase and option agreement dated February 26, 2021 (the “Purchase Agreement“) with First Cobalt Corp. (“FCC“), Cobalt Industries of Canada Inc. (“CIC“) and CobalTech Mining Inc. (“CobalTech“), the Company has acquired a portion of FCC’s silver mineral exploration assets (the “Kerr Assets” or the “Kerr Project“) from FCC (the “Transaction“) as previously announced on December 21, 2020. Pursuant to the terms of the Purchase Agreement, the Company has also acquired from CIC an option to acquire up to a seventy percent (70%) interest in and to the balance of FCC’s silver mineral assets (“Remaining Assets“) located in the historic Cobalt, Ontario silver mining district (the “Option“).

Kuya’s President and CEO, David Stein stated, “This world class silver mining district has been largely abandoned for the past thirty years, and Kuya is excited to sink our teeth into this project. Kuya has identified the opportunity to follow up on recently discovered high-grade silver mineralization and plans to focus on these high-priority areas in our first phase of exploration. Our goal here is to build enough tonnage to justify a new Ontario silver mine that would be the platform to grow production in the district over time. In addition to the Kerr Project, we look forward to working with First Cobalt on the Silver Kings Joint Venture, where we will take a bigger picture approach and target the discovery of new clusters of veins, which have been the focus of the vast majority of historical production in the district.”

Dr. Quinton Hennigh, Kuya Chairman commented, “The extremely high-grade silver veins of the Cobalt camp occur along high-angle structures that transect the Nipissing diabase sill. Best grades tend to occur in host rocks immediately above or below this sill. When this project is viewed with that model in mind, it is easy to see that most of our tenure is underlain by unexplored or poorly explored areas with potential for both hanging wall and footwall vein targets. We plan to set about building a comprehensive model of historic data as well as collect new data that will allow us to identify new structures that might host high-grade silver mineralization. This camp is world class in every respect, and we see exceptional potential for further discovery.”

Pursuant to the Purchase Agreement, the Company has paid FCC a cash payment of $500,000, with a further $500,000 to follow subject to the satisfaction of certain post-closing conditions, and issued 1,437,470 common shares in the capital of the Company (each a “Common Share“) at a deemed price per Common Share based on the twenty (20) day volume weighted average trading price of the Common Shares (the “20 Day VWAP“), prior to the announcement of the Transaction on December 21, 2020, being $2.087 per Common Share to acquire 100% of the Kerr Assets.

In order to fully exercise the Option on the Remaining Assets, the Company is to:

  • On or prior to the date that is six months from the closing date (“the Earn-In Date“) of the Transaction, pay to CIC $1,000,000 (“Initial Earn-In Payment“).
  • In exchange for a forty-nine percent (49%) interest in the Remaining Assets, on or prior to the date that is twelve (12) months from the Earn-In Date pay to CIC $300,000 (or an equivalent in Common Share at the 20 Day VWAP of the Common Shares prior to such payment being made) and having incurred expenditures of no less than $2,000,000 in and to the Remaining Assets.
  • In exchange for an additional eleven percent (11%) interest in the Remaining Assets on, or prior to the date that is twenty-four (24) months from the Earn-In Date pay to CIC $350,000 (or an equivalent in Common Shares at the 20 Day VWAP prior to such payment being made) and having incurred expenditures of no less than $1,000,000 in and to the Remaining Assets; and,
  • In exchange for an additional ten percent (10%) interest in the Remaining Assets on, or prior to the date that is thirty-six (36) months from the Earn-In Date, pay to CIC $350,000 (or an equivalent in Common Shares at the 20 Day VWAP prior to such payment being made) and having incurred expenditures of no less than $1,000,000 in and to the Remaining Assets.

As part of the terms of the Transaction, FCC will spend $1 million of the flow through proceeds it raised in 2020 on eligible expenditures, split equally between the Kerr Assets and the Remaining Assets. In connection with the Option, upon completion of a maiden mineral resource estimate of at least 10,000,000 silver equivalent ounces on the Remaining Assets, the Company will make a milestone payment to FCC of $2,500,000 million in cash or Common Shares (at the 20 Day VWAP) or $5,000,000 should the resource exceed 25,000,000 silver equivalent ounces, such milestone payment to continue to be an obligation of the Company for a period of eighteen (18) months following the discovery of the maiden mineral resource. Further, with respect to the Remaining Assets, FCC will have a back?in right for any discovery of a primary cobalt deposit as well as a right of first offer to refine base metal concentrates produced at FCC’s refinery.

Following the payment of the Initial Earn-In Payment, the Company and CIC will enter into a joint venture agreement on terms to be negotiated for the joint exploration and development of the Remaining Assets.

All Common Shares issued in connection with the Transaction are subject to a four-month and one day resale restriction from the date of closing, being July 2, 2021.

Introducing the Silver Kings Project in Ontario’s most famous silver mining camp

The entire 10,000-hectare land package consisting of the 100%-owned Kerr Project together with the joint venture with FCC will be known as the Silver Kings Project and the joint venture will be referred to as the Silver Kings Joint Venture. Initially Kuya’s focus will be on the Kerr Project, where the vast majority of First Cobalt’s 35,000 m 2017-2018 shallow drill program occurred. The Kerr Project includes several historic silver mines including Crown Reserve, Silver Leaf, Kerr Lake, Drummond, Hargrave, Silverfields and others which collectively produced an estimated 70 million ounces of silver. FCC identified several bonanza-style silver intercepts while exploring for cobalt, and Kuya intends to follow up on these intersections with new drilling in order to determine the extent of the high-grade silver mineralization. Kuya has identified potential for both extensions to previously-mined silver veins and new discoveries in the recent drilling.

Kuya is planning to start a Phase 1 exploration program at the Kerr Project immediately, which will include a 2,500 m drilling program and is being budgeted to match a $500,000 flow-through expenditure commitment by FCC.

Some of Kuya’s higher priority initial targets include:

  • Kerr Mine area where drill-hole FC-18-0058 intersected 3.57 m of 821 g/t silver and 0.45% cobalt (including 1.57 m of 1,756 g/t silver and 0.71% cobalt) from 29.43 m.
  • Silver Leaf Mine area where drill-hole FC-18-0174 intersected 2.5 m of 1,441 g/t silver and 0.28% cobalt from 66.0 m.
  • Drummond Mine area where drill-hole FC-18-0094 intersection 2.0 m of 450* g/t silver and 0.10% cobalt from 20.0 m.
  • A potential new zone north of the Kerr and Drummond Mines where drill-hole FC-18-0093 intersected 2.2 m of 515* g/t silver and 0.61% cobalt (including 0.7 m of 1,460* g/t silver and 1.81% cobalt) from 1.72.1 m.

*Individual silver assays capped at 1500 g/t included in reported intersection

Kuya is currently working with FCC to plan an initial geological program on the Silver Kings Joint Venture and allocation of the $500,000 flow-through expenditure. Kuya is targeting a drill program on the JV later in the year.

National Instrument 43-101 Disclosure

The technical content of this news release has been reviewed and approved by Dr. Quinton Hennigh, P.Geo., Chairman of Kuya and a Qualified Person as defined by National Instrument 43-101.

About Kuya Silver Corporation

Kuya is a Canadian-based silver-focused mining company that owns the Bethania Project, which includes the Bethania mine, located in Central Peru. The Bethania mine was in production until 2016, toll?milling its ore at various other concentrate plants in the region, the Company’s plan is to implement an expansion and construct a concentrate plant at site before restarting operations. The Bethania mine produced silver?lead and zinc concentrates from the run of mine material, until being placed on care and maintenance due to market conditions and lack of working capital.

For more information, please contact the Company at:

Kuya Silver Corporation
Telephone: (604) 398-4493
[email protected]
www.kuyasilver.com

Reader Advisory

This news release may contain statements which constitute “forward-looking information”, including statements regarding the plans, intentions, beliefs and current expectations of the Company, its directors, or its officers with respect to the future business activities of the Company. The words “may”, “would”, “could”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” and similar expressions, as they relate to the Company, or its management, are intended to identify such forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future business activities and involve risks and uncertainties, and that the Company’s future business activities may differ materially from those in the forward-looking statements as a result of various factors, including, but not limited to, fluctuations in market prices, successes of the operations of the Company, continued availability of capital and financing and general economic, market or business conditions. There can be no assurances that such information will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. The Company does not assume any obligation to update any forward-looking information except as required under the applicable securities laws.



Neither the Canadian Securities Exchange nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release.

Source: Kuya Silver

Release – electroCore Inc. (ECOR) – Announces Exclusive Distribution Agreement with Medistar


electroCore Inc. Announces Exclusive Distribution Agreement with Medistar Following Regulatory Approval in Australia

 

ROCKAWAY, N.J., Feb. 28, 2021 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has entered into an agreement with Medistar2 PTY Limited (“Medistar”) whereby Medistar will serve as the exclusive distributor of the gammaCore Sapphire™ non-invasive vagus nerve stimulator (nVNS) in Australia, supplying therapy to patients suffering with primary headache disorders. The announcement follows the granting of regulatory approval from the Australian Therapeutic Goods Administration (TGA) for the promotion and sale of the gammaCore Sapphire family of products.

“We are delighted to welcome Jeneth Boughen, Owner and General Manager of Medistar, and the team at Medistar into our growing network of select distribution partners,” said Iain Strickland, electroCore’s Vice President of European Operations. “Medistar has demonstrable expertise in medical device distribution in Australia and we are incredibly excited to have its team working on behalf of electroCore.”

“Medistar is very excited to be partnering with electroCore to help Australians access gammaCore Sapphire (nVNS) therapy and assist healthcare professionals to add this treatment option to their medical practice,” said Jeneth Boughen, Owner and General Manager of Medistar. “Our mission is to partner with suppliers and health professionals to provide education and support for innovative technologies that improve efficiencies, patient well-being and outcomes. We see strong alignment between ourselves, electroCore and its non-pharmacological therapy for Australians who do not tolerate or respond well to current headache therapies.”

The initial term of the agreement is three years and contains customary terms and conditions, including minimum purchase commitments. Medistar will be officially launching gammaCore Sapphire at the 2021 ANZHS Headache Annual Scientific Meeting, which will be held on March 13-14. For more information on the ANZHS Headache Annual Scientific Meeting, please visit: https://anzheadachesociety.org/events/

“This is a welcome addition to the armamentarium in the treatment of refractory headache syndromes. We have good evidence of the efficacy of gammaCore, and being drug free, it reduces the medication side effect burden patients experience,” commented Dr. Marc Russo, Specialist Pain Medicine Physician and Director-at-Large of the Neuromodulation Society of Australia and New Zealand. “Beside this, gammaCore is an exciting tool to explore interfacing with the vagus nerve and the anti-inflammatory pathway. Treating headache may just be the tip of the iceberg of what we can do with this device.”

About Medistar

Medistar is an Australian independent medical device distributor recognised for supplying cutting edge technologies to health and veterinary professionals in Australia and New Zealand. The company represents best in class medical devices in the pain management, ultrasound and neurological sectors. For more information, visit https://medistar.com.au

About electroCore, Inc.

electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology. The company’s current indications are the preventative treatment of cluster headache and migraine and acute treatment of migraine and episodic cluster headache. For more information, visit www.electrocore.com.

About gammaCore™

gammaCore™ (nVNS) is the first non-invasive, hand-held medical therapy applied at the neck as an adjunctive therapy to treat migraine and cluster headache through the utilization of a mild electrical stimulation to the vagus nerve that passes through the skin. Designed as a portable, easy-to-use technology, gammaCore can be self-administered by patients, as needed, without the potential side effects associated with commonly prescribed drugs. When placed on a patient’s neck over the vagus nerve, gammaCore stimulates the nerve’s afferent fibers, which may lead to a reduction of pain in patients.

gammaCore is FDA cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, and the acute and preventive treatment of migraine in adolescent (ages 12 and older) and adult patients. gammaCore is CE-marked in the European Union for the acute and/or prophylactic treatment of primary headache (Migraine, Cluster Headache, Trigeminal Autonomic Cephalalgias and Hemicrania Continua) and Medication Overuse Headache in adults.

  • gammaCore is contraindicated for patients with:
    • An active implantable medical device, such as a pacemaker, hearing aid implant, or any implanted electronic device
    • A metallic device, such as a stent, bone plate, or bone screw, implanted at or near the neck
    • An open wound, rash, infection, swelling, cut, sore, drug patch, or surgical scar(s) on the neck at the treatment location
  • Safety and efficacy of gammaCore have not been evaluated in the following patients:
    • Patients diagnosed with narrowing of the arteries (carotid atherosclerosis)
    • Patients who have had surgery to cut the vagus nerve in the neck (cervical vagotomy)
    • Pediatric patients (younger than 12 years)
    • Pregnant women
    • Patients with clinically significant hypertension, hypotension, bradycardia, or tachycardia

Forward-Looking Statements

This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore’s business prospects and clinical and product development plans; its pipeline or potential markets for its technologies; the timing, outcome and impact of regulatory, clinical and commercial developments; the business, operating or financial impact of such studies; the commercial potential of nVNS generally and gammaCore in particular in Australia and other statements that are not historical in nature, particularly those that utilize terminology such as “anticipates,” “will,” “expects,” “believes,” “intends,” other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue electroCore’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize gammaCore™, the potential impact and effects of COVID-19 on the business of electroCore, electroCore’s results of operations and financial performance, and any measures electroCore has and may take in response to COVID-19 and any expectations electroCore may have with respect thereto, competition in the industry in which electroCore operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with the SEC available at www.sec.gov.

Investors:
Hans Vitzthum
LifeSci Advisors
617-430-7578
[email protected]

Media Contact:
Summer Diaz
electroCore
816-401-6333
[email protected]

Source: electroCore

Release – ACCO Brands (ACCO) – Announces Private Offering of $650 Million of Senior Unsecured Notes


ACCO Brands Corporation Announces Private Offering of $650 Million of Senior Unsecured Notes

 

LAKE ZURICH, Ill.–(BUSINESS WIRE)– ACCO Brands Corporation (NYSE: ACCO), one of the world’s largest designers, marketers and manufacturers of branded academic, consumer and business products, today announced a private offering of $650 million of senior unsecured notes due 2029. The company intends to use the proceeds from the offering to redeem all $375 million outstanding principal amount of its 5.25% senior unsecured notes due December 2024, to repay a portion of its outstanding borrowings under its secured revolving credit facility and to pay fees and expenses related to the offering. The redemption of the existing notes will be conditioned on completion of the offering of the new notes.

The notes will be offered only to persons reasonably believed to be qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended, and outside of the United States only to non-U.S. investors pursuant to Regulation S. The notes will not be registered under the Securities Act or any state securities laws and may not be offered or sold in the United States absent an effective registration statement or an applicable exemption from registration requirements or a transaction not subject to the registration requirements of the Securities Act or any state securities laws.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offering, solicitation or sale would be unlawful. Any offers of the notes will be made only by means of a private offering memorandum. This press release is for informational purposes only and does not constitute a notice of redemption.

About ACCO Brands Corporation

ACCO Brands Corporation is one of the world’s largest designers, marketers and manufacturers of branded academic, consumer and business products. Our widely recognized brands include AT-A-GLANCE®, Barrilito®, Derwent®, Esselte®, Five Star®, Foroni®, GBC®, Hilroy®, Kensington®, Leitz®, Mead®, PowerA®, Quartet®, Rapid®, Rexel®, Swingline®, Tilibra®, Wilson Jones®, and many others. Our products are sold in more than 100 countries around the world.

Forward-Looking Statements

Statements contained in this press release, other than statements of historical fact, particularly statements regarding the our intention to complete the offering of notes, redeem our existing notes and repay a portion of our outstanding revolving credit facility borrowings, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on the beliefs and assumptions of management based on information available to us at the time such statements are made. These statements, which are generally identifiable by the use of the words “will,” “believe,” “expect,” “intend,” “anticipate,” “estimate,” “forecast,” “project,” “plan,” and similar expressions, are subject to certain risks and uncertainties, are made as of the date hereof, and we undertake no duty or obligation to update them whether as a result of new information, future events or otherwise. Because actual results may differ materially from those suggested or implied by such forward-looking statements, you should not place undue reliance on them when deciding whether to buy, sell or hold the company’s securities.

Among the factors that could cause our actual results to differ materially from these forward-looking statements are general market and other conditions that may adversely impact our ability to complete the notes offering and the redemption of our existing notes on terms favorable to the company, or at all, as well as the other risks and uncertainties described in “Part I, Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2020, and in other reports we file with the Securities and Exchange Commission. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the foregoing cautionary statements.

Christine Hanneman
Investor Relations
(847) 796-4320

Julie McEwan
Media Relations
(937) 974-8162

Source: ACCO Brands Corporation

Grindrod Shipping (GRIN) – 2H2020 Results Below Expectations But Transitioning to More Positive Outlook

Monday, March 01, 2021

Grindrod Shipping (GRIN)
2H2020 Results Below Expectations But Transitioning to More Positive Outlook

Grindrod Shipping, originated in South Africa with roots dating back to 1910. The company is based in Singapore, with offices around the world including, London, Durban, Cape Town, Tokyo and Rotterdam. Its primary listing is on Nasdaq and secondary listing on the JSE.

Grindrod Shipping owns and operates a diversified fleet of owned, long-term chartered and joint-venture dry-bulk and liquid-bulk vessels across the globe.

Poe Fratt, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Despite improved dry bulk market outlook, 2H2020 results lagged. Reported 2H2020 EBITDA of $18.5 million dropped from 2H2019 EBITDA of $25.1 million even though the dry bulk market fundamentals started to improve in late 1H2020. Adjusting for IFRS 16 adoption, we calculate that adjusted EBITDA was $12.8 million in 2H2020, which was below expectations.

    Fine tuning 2021 EBITDA estimate.  Dry bulk market thesis intact. Given the firmer state of the dry bulk market, we are fine-tuning our 2021 EBITDA to $52.6 million from $52.0 million. There is limited visibility into this year, but the year is off to a good start. Supramax rates averaged ~$10.8k/day in 2H2020 and are currently above $20.0k/day, which is counter to normal seasonality. While we …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Why Researching Investment Ideas is Important

 


Blockchain, Beverages, and Baloney

 

Blockchain is a digital distributed ledger of transactions in a decentralized database. It continuously updates digital records in real-time across a network of computers. As a means of eliminating huge amounts of record-keeping, its use is very powerful. But the word “blockchain” by itself also has power; the very word, at times has taken the lead driving stock price.  Just adding it to a company name, has in the past, attracted new investors to the company’s stock. There were times when innocent, unaware investors have been duped.

A Lesson in Blockchain Frenzy

The year was 2017. The cryptocurrency market was experiencing an amazing bull run which drove bitcoin past $20,000 for the first time (by late 2018 it fell back below $4,000). Many speculative digital coin offerings were springing up during this crypto-frenzy. A large percentage of these so-called blockchain projects were barely legitimate or outright scams.

The Long Island Iced Tea Company (OTC: LBCC) was trading at about $3 per share.  They decided to rebrand their modestly successful beverage company to perhaps take advantage of capital that was flowing into the digital asset space. The beverage maker made a simple name change to Long Branch Chain Company and had its ticker symbol adjusted from LTEA to LBCC. This move led to an almost immediate tripling of the bottled tea’s stock price.

Other than the name change, the LBCC’s blockchain strategy was never defined. Management had early on stated that it would be “shifting its primary corporate focus toward the exploration of and investment in opportunities that leverage the benefits of blockchain technology.” LBCC had also announced plans to acquire Bitcoin mining hardware. These plans were never carried out. The Nasdaq stock exchange eventually delisted the company, in part because they believed management was not being forthright with investors. This caused the stock that had at one time approached $10 to fall to $1.10 per share. The delisting pushed investors to over-the-counter desks to exchange shares.

 

 

Long Island Iced Tea Update

This past week, on February 22, almost three years after the name change, the U.S. Securities and Exchange Commission (SEC) revoked Long Blockchain’s stock registration. This revocation effectively bans or prevents public investors from trading in the company’s shares. The SEC stated that Long Island’s “blockchain business never became operational” and that the firm has failed to report on its financial results for the past 3 years.

The company is still making its beverages, primarily ready-to-drink iced tea and lemonade, under the “Long Island” brand.

Investment Lesson

Information, both trustworthy and dubious is plentiful in today’s digital communication world. We’re now aware of more options of things we can do with our money and we have more ways to investigate. Looking behind the curtain should be easier than ever. Hardly anyone makes a retail purchase like an appliance without reading reviews. Dining out at a new restaurant, for many,  involves checking to see how many stars Yelp visitors have given it.  Investing in a company is arguably more important than buying a microwave or ordering a poke bowl. Yet, credible company research is often the last place many investors turn, even though it can steer them through hype. There are layers of information from management plans, to accounting methods, to the industry as a whole that investors should, if not understand, find a source of trustworthy research.

Investors chasing companies because the crowd is or because it gives the appearance of being involved in something it isn’t can be avoided. Present-day examples of companies rebranding to attract capital is, of course, the so-called covid stocks. There are many examples of companies rebranding or getting their name viewed as a Covid Stock that probably should not be. The result is a dramatic increase in the volume of shares traded and share price. For example, Kodak (KODK) climbed 2,441% in one week last year by rebranding itself as a covid stock. It wouldn’t surprise me if begin to see the same with “green” publicly traded companies.

It’s more critical than ever to read the “reviews” and find out how many “stars” something is given and why. In the world of trading equities, this means finding company research providers of high integrity and heightened knowledge of the company.

 

 

Research, analysis, and company data are reasons why Channelchek’s usage keeps expanding. Registered users on the platform are free to explore what veteran, FINRA registered equity analysts are saying. With tens of thousands of research downloads and even more investors hearing directly from companies’ management on the YouTube channel, regular visitors to Channelchek are apt to improve their chances of being able to read the tea leaves.

Take-Away

Make it your business to know what you’re investing in and know what you own. Find sources of analysis you trust. Treat every investment with more care than a $25 Amazon purchase. Beware of artificially sweetened tea offerings. And, with the current frenzy toward ESG, be cautious, it’s not that easy being green.

 

Paul Hoffman

Managing Editor, Channelchek

 

Suggested Reading:

Small-Cap Names in a Big Crypto Market

Managing Investment Portfolio Risk

Lithium Ion Battery Recycling Heats Up

 

 

Sources:

https://www.sec.gov/Archives/edgar/data/1629261/000149315218001393/ex99-1.htm

https://www.sec.gov/Archives/edgar/data/1629261/999999999721000824/filename1.pdf

https://www.coindesk.com/nasdaq-believes-publicly-traded-firm-long-blockchain-mislead-investors

https://www.coindesk.com/nasdaq-believes-publicly-traded-firm-long-blockchain-mislead-investors

https://www.crowdfundinsider.com/2017/12/126347-former-long-island-iced-tea-corp-now-long-blockchain-corp-signs-convertible-debt-facility-support-blockchain-pivot/

https://arstechnica.com/tech-policy/2017/12/iced-tea-company-stock-triples-after-adding-blockchain-to-name/

https://www.crowdfundinsider.com/2017/12/126259-long-blockchain-corp-withdraws-proposed-public-offering-company-pivots-beverage-based-business/

https://stocktwits.com/symbol/LBCC

https://www.coindesk.com/long-blockchain-risk-exchange-removal

Stay up to date. Follow us:

           


Stay up to date. Follow us:

Kratos Defense & Security (KTOS) – 4Q20 Results In-line

Friday, February 26, 2021

Kratos Defense & Security (KTOS)
4Q20 Results In-line

Kratos Defense & Security Solutions is a National Security technology provider with proprietary expertise in the area of unmanned aerial vehicles, electronics for missile defense systems, electronic warfare systems, satellite control and management systems and support services for emerging naval weapon systems. Commercial and state and local government revenues are about 25% of the total and comprise primarily of critical infrastructure monitoring and protection systems.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Market Perform. KTOS shares have exceeded our PT but we view 2021 as a re-set year, with many programs having been pushed to the right due to COVID. We still believe in the long-term prospects of Kratos and believe the Company to be well positioned to capitalize on new and emerging trends in defense.

    4Q20 Results.  Revenue rose 11.5% to $206.4 million. Adjusted EPS was $0.08 compared to $0.09 last year. Adjusted EBITDA for the quarter totaled $22.3 million, up 10.4% from $20.2 million in 4Q19. We had projected revenue of $210 million, adjusted EPS of $0.09, and Adjusted EBITDA of $20 million. Consensus was $217 million and $0.10. Unmanned Systems revenues grew 29.2% to $49.5 million, reflecting …



This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Orion Group Holdings (ORN) – Better-than-Expected Quarter, But Flat Year Ahead?

Friday, February 26, 2021

Orion Group Holdings (ORN)
Better-than-Expected Quarter, But Flat Year Ahead?

Orion Group Holdings, based in Houston, Texas, is a specialty construction company within the Marine and Industrial Construction sectors, with operations focused in the continental United States and Caribbean. Revenue is split roughly 50/50 between a Marine Construction segment that provides marine facility, pipeline and structural construction services and a Commercial Concrete segment that provides turnkey concrete services in the light commercial and structural construction markets.

Poe Fratt, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    4Q2020 EBITDA of $12.6 million beat guidance of $10-$12 million and 2020 EBITDA of $54.4 million sets the bar high for 2021. Excluding asset sales, 2020 EBITDA was $48.2 million. Despite the uncertain operating environment, 4Q2020 operating results exceeded expectations. Versus last year, gross profit increased to $21.7 million from $19.1 million, and EBITDA also improved to $12.6 million from $11.0 million. Revenue dropped off almost $30 million to $170.2 million, but profitability was solid, with higher gross margin of 12.8% (+320 basis points) and EBITDA margin of 7.7% (+220 basis points).

    Fine tuning 2021 EBITDA estimate to $47.0 million from $48.7 million to reflect more conservation tack.  Tough comps versus 2020 EBITDA of $48.2 million, but profitability remains solid with EBITDA margin in 6.9% range …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Release – Xtant Medical (XTNT) – Announces Closing of $20 million Private Placement

 


Xtant Medical Announces Closing of $20 million Private Placement

 

BELGRADE, Mont., Feb. 25, 2021 (GLOBE NEWSWIRE) — Xtant Medical Holdings, Inc. (NYSE American: XTNT, the “Company”), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the closing of its previously announced $20 million private placement to a single healthcare-focused institutional investor. The Company sold 8,888,890 common shares and warrants to purchase 6,666,668 common shares at a combined purchase price of $2.25 per share. The warrants have an exercise price of $2.25 per share, are immediately exercisable and will expire five years from the date of issuance. After deducting fees and other estimated offering expenses, the Company received net proceeds of approximately $18.4 million.

The Company expects to use the net proceeds from the private placement for working capital and other general corporate purposes.

“This capital provides Xtant with additional resources that can be used to advance our key growth initiatives and our strategic goals, which will help us drive greater shareholder value as we focus on our mission of ‘honoring the gift of donation by allowing our patients to live as full a life as possible,’” said Sean Browne, President and CEO of Xtant.

A.G.P./Alliance Global Partners served as sole placement agent for the private placement.

The private placement is complete and was made pursuant to the exemption from securities registration afforded by Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506 of Regulation D as promulgated by the United States Securities and Exchange Commission (SEC) and the securities sold in the private placement may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. The Company has agreed to file a registration statement with the SEC covering the resale of the common shares as well as the common shares issuable upon exercise of the warrants issued in the private placement.

This release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About Xtant Medical Holdings, Inc.

Xtant Medical Holdings, Inc. is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Xtant’s people are dedicated and talented, operating with the highest integrity to serve our customers.

The symbols ™ and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as “expects,” “intends,” “plans,” “anticipates,” “believes,” “future,” “will,” “may,” “continue,” similar expressions or the negative thereof, and the use of future dates. Forward-looking statements in this release include the Company’s expectations regarding the amount and its use of the net proceeds from the private placement, including advancing its key growth initiatives and strategic goals and driving greater shareholder value. The Company cautions that its forward-looking statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: risks and uncertainties surrounding the private placement; the effect of the COVID-19 pandemic on the Company’s business, operating results and financial condition; the Company’s future operating results and financial performance; the ability to increase or maintain revenue; the ability to remain competitive; the ability to innovate and develop new products; the ability to engage and retain qualified personnel; government and third-party coverage and reimbursement for Company products; the ability to obtain and maintain regulatory approvals and comply with government regulations; the effect of product liability claims and other litigation to which the Company may be subject; the effect of product recalls and defects; the ability to obtain and protect Company intellectual property and proprietary rights and operate without infringing the rights of others; the ability to service Company debt, comply with its debt covenants and access additional indebtedness; the ability to obtain additional financing on favorable terms or at all and other factors. Additional risk factors are contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 filed with the SEC on February 24, 2021. Investors are encouraged to read the Company’s filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by this cautionary statement.

Investor Relations Contact

David Carey
Lazar FINN
Ph: 212-867-1762
Email: [email protected]

SOURCE: Xtant Medical Holdings, Inc.

QuickChek – February 26, 2021



Ocugen up 18% in late-day trading

Brazil’s Health Ministry on Thursday signed a contract to purchase 20 million doses of Covaxin, the COVID-19 vaccine made by India’s Bharat Biotech. Ocugen recently finalized an agreement with Bharat to co-develop Bharat’s Covid-19 vaccine for the United States market.

Research, News & Market Data on Ocugen

Watch recent presentation from NobleCon17



Xtant Medical Announces Closing of $20 million Private Placement

Xtant Medical Holdings, Inc. announced the closing of its $20 million private placement to a single healthcare-focused institutional investor. The Company sold 8,888,890 common shares and warrants to purchase 6,666,668 common shares at a combined purchase price of $2.25 per share.

News & Market Data on Xtant Medical




Lixte Biotechnology to Present Its Anti-Cancer Therapy Enhancer LB-100

Lixte Biotechnology Holdings, Inc. announced it will present Its Anti-Cancer Therapy Enhancer LB-100 at the Virtual H.C. Wainwright Global Life Sciences Conference being held March 9-10, 2021.

News & Market Data on Lixte Biotechnology


Stay up to date. Follow us:

           


Stay up to date. Follow us:

The Correlation Between Stocks and Unemployment

 


Why Elevated Unemployment isn’t Hurting Stocks

 

Trends in unemployment and the coinciding trend in stock market valuation have run counter to each other over the years. It is not a 100% negative correlation as stock market strength, and weakness tends to also follow other measures. These could include disposable income, consumer optimism, debt levels, and other factors. The other related measures don’t always track each other, so one factor normally takes precedence. Often, it’s whichever indicator the market decides to give more weight to in any time period — when they’re headed in different directions, the market obviously can’t move with them all.  But, unemployment as a contra-indicator of overall market direction is very strong.

It was reported yesterday by the BLS that Jobless claims declined by 111,000 from the previous week to a seasonally adjusted 730,000. This is the lowest in over two months and the sharpest one-week decline since August. The direction seems positive, but prior to last March, unemployment benefits had never (notice no time period in “never”) topped 700,000. The percentage unemployed in April 2020 reached 14.7% which is the highest rate since the Great Depression.

How Important is the Rate of Unemployment?

Direction matters to the market more than any absolute number. Market participants want to know if something is getter better or worse than yesterday, not a year ago, or even 90 years ago.

The most recent relationship coincides with a weakened job market that has not grown since the 2020 election.  Hiring has averaged only 29,000 a month from November through January. Numbers can be deceiving as well. Although the headline unemployment rate reported was 6.3% in January, a broader measure that incorporates those that may have become exasperated and discontinued their job search, borders on 10%.  So the picture is improving but not good by many standards.

All told, 19 million people were receiving unemployment aid as of Feb. 6, up from 18.3 million the previous week. About three-quarters of those recipients are receiving checks from federal benefit programs, including programs that provide jobless aid beyond the 26 weeks provided for in most states.

A Look at the S&P 500 Versus Unemployment  over the past 20-years (Orange line is Unemployment
as reported by the BLS)

 

Last week’s drop in applications was concentrated in two states, California and Ohio, where they fell by a combined 96,000. Ohio officials had said earlier this month that a surge in new applications was driven in part by a jump in potentially fraudulent claims. That now appears to have faded. Other factors outside the norm that may have impacted the numbers are the winter storms and power grid problems in Texas during the week. It’s difficult to factor out that “noise” and there is always a certain level of noise including natural disasters, fraudulent claims, temporary industry shutdowns, etc.

It helps to see the way unemployment and the market (measured by the S&P 500) track in order to visualize if we have deviated from an established pattern. Obviously, a pattern that is easy to get your head around, when a lot of people are out of jobs and the economy isn’t very promising, stocks sink. And when the unemployment rate drops because payroll numbers have risen, stocks rise. Keep reading, so you know just how closely correlated the two are. 

Look at that chart above; the two lines are almost perfect inverses to each other, until the coronavirus spike last Spring. They cross during large economic shifts such as the dot-com bubble around Y2k, again at the 2008-2009 financial crisis, ad in 2014 as the unemployment rate perked up to pre-recession lows, stocks climbed to new highs. Last year the two lines raced in opposite directions when the decision was made to reduce the number of people headed to a job every day.  Since the economic shutdown, the unemployment rate has been reduced by more than half after reaching 14.7% last April. As for stocks, they have risen about 70%, from the late March 2020 bottom. The market improved some before the jobless rate fell; this is likely in anticipation of the improvement. A decrease in those unemployed was presumed to be easy to anticipate as a turn in the economy was presumed to be hinged on medical approvals in the works.

Take-Away

It is not irrational to understand why stocks are near their all-time highs while unemployment is near their numerical highs. As long as the unemployment rate continues to fall, history suggests stocks will continue to rise. The weekly employment numbers contain information worth paying attention to under any economic conditions.

Do you expect a year from now, the U.S. unemployment rate will be lower than today?  Factor that into your stock market forecast. What actually happens remains to be seen. Over the past 20 years, the unemployment-stock market correlation has held a reliable inverse relationship. Is the market still ahead of itself in predicting further improvement in stocks? As always, we can only look at stats from the past, never the future.

 

Suggested Reading:

What Stocks do You Buy When the Dollar Goes Down?

How Did the Stock Market Perform Under Each President?

Managing Investment Portfolio Risk

 

 

Sources:

Unemployment Insurance Weekly Claims

Stay up to date. Follow us:

           


Stay up to date. Follow us: